AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
AbbVie (ABBV) Tops Q4 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
February 4, 2026 7:51 AM ESTAbbVie (NYSE: ABBV) reported Q4 EPS of $2.71, $0.06 better than the analyst estimate of $2.65. Revenue for the quarter came in at $16.62 billion versus the consensus estimate of $16.39 billion.
GUIDANCE:
AbbVie sees FY2026 EPS of $14.37-$14.57, versus the consensus of $14.22.
For earnings history and earnings-related data on AbbVie (ABBV) click here.
... More